FDA-Approved Uses for Lurbinectedin
Lurbinectedin (Zepzelca) is approved by the FDA for treating metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1] This approval came in June 2020 based on the phase 2basket trial showing a 35% overall response rate.[1]
Investigational Uses in Other Cancers
Lurbinectedin is under study for several other solid tumors, often in combination with other agents like irinotecan or doxorubicin:
- Mesothelioma: Phase 2 trials tested it in malignant pleural mesothelioma, reporting a 25% response rate in pretreated patients.[2]
- Triple-Negative Breast Cancer (TNBC): Early trials showed antitumor activity, with ongoing phase 2 studies evaluating combinations.[3]
- Ovarian Cancer: Phase 2 data indicate responses in platinum-resistant cases, particularly BRCA-mutated subtypes.[4]
- Uterine Leiomyosarcoma and Soft Tissue Sarcomas: Responses observed in phase 2 basket trials, leading to further sarcoma-specific studies.[2][5]
- Thymic Carcinoma and Other Rare Tumors: Single-agent activity noted in thymic epithelial tumors and endometrial cancer in expanded access programs.[3]
These are not approved indications; efficacy varies by trial and patient selection.
Ongoing Clinical Trials
Over 50 active trials (as of 2023) explore lurbinectedin across cancers including colorectal, prostate, bladder, head and neck, and pancreatic, mostly in advanced or refractory settings.[6] For example:
- NCT04702737 tests it with atezolizumab in SCLC and extrapulmonary neuroendocrine carcinomas.
- NCT04186083 evaluates it in endometrial cancer post-platinum therapy.
Check ClinicalTrials.gov for recruitment status and eligibility.
How Lurbinectedin Works Across Cancer Types
As a selective inhibitor of oncogenic transcription, lurbinectedin traps DNA complexes in cancer cells with high transcription rates, like SCLC and sarcomas. This mechanism suits transcriptionally active tumors, explaining its broad phase 2 signals despite SCLC focus.[7] Response rates drop in less dependent cancers like colorectal.
Limitations and Patient Considerations
No approvals beyond SCLC; off-label use is rare due to IV administration and risks like myelosuppression (35% grade 3/4 neutropenia).[1] Trials often exclude poor performance status patients. Patent protection lasts until at least 2031 in the US.[8]
Sources:
[1]: FDA Label for Zepzelca
[2]: J Clin Oncol. 2021;39(suppl):3106
[3]: Ann Oncol. 2020;31(suppl_4):S1152-S1185
[4]: Clin Cancer Res. 2022;28:305-315
[5]: Invest New Drugs. 2021;39:1690-1697
[6]: ClinicalTrials.gov search for lurbinectedin
[7]: Mol Cancer Ther. 2016;15:260-269
[8]: DrugPatentWatch.com - Zepzelca patents